A Study to Evaluate the Efficacy and Safety of AD-223

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 502 participants.

Also called NCT06052748

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 502 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06052748
Other papers using this trial's data
  • Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial Journal of clinical hypertension (Greenwich, Conn.), 2026-05 DOI, PubMed 42130156, PMC13172608 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06052748. Randomized; double masking; primary purpose treatment. Start 2024-02-15 (actual); primary completion 2025-03-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AD-223
Condition
Hypertension,Essential
Intervention (Drug)
AD-223A
Intervention (Drug)
AD-223B
Intervention (Drug)
AD-223C
Intervention (Drug)
AD-223A Placebo
Intervention (Drug)
AD-223B Placebo
Intervention (Drug)
AD-223C Placebo
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct06052748
Content hash
7ad1145b069890bb58b26cdb3e2480d4eaf7e002342f85f76d84c78106ae0a22